🚀 VC round data is live in beta, check it out!
Chong Kun Dang Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Chong Kun Dang Pharma and similar public comparables like Design Therapeutics, Vor Biopharma, ARS Pharmaceuticals, Lexicon Pharmaceuticals and more.
Chong Kun Dang Pharma Overview
About Chong Kun Dang Pharma
Chong Kun Dang Pharmaceutical Corp. is a manufacturer of antibiotics. The company manufactures and distributes over 130 ethical, OTC pharmaceuticals and pharmaceutical active ingredients, primarily focusing on the application of its advanced technologies in fermentation and organic synthesis. The product range includes Rifampicin (antituberculosis), DMCT (raw material for Minocycline), Cephalosporins, 7-ACA and other intermediates of Cephalosporins, Cyclosporin A (immunosuppressant) and Lovastatin (antihyperlipidaemic agent).
Founded
1941
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$819M
Chong Kun Dang Pharma Financials
Chong Kun Dang Pharma reported last 12-month revenue of $1B and EBITDA of $84M.
In the same LTM period, Chong Kun Dang Pharma generated $359M in gross profit, $84M in EBITDA, and $57M in net income.
Revenue (LTM)
Chong Kun Dang Pharma P&L
In the most recent fiscal year, Chong Kun Dang Pharma reported revenue of $1B and EBITDA of $90M.
Chong Kun Dang Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | $359M | XXX | $356M | XXX | XXX | XXX |
| Gross Margin | 31% | XXX | 31% | XXX | XXX | XXX |
| EBITDA | $84M | XXX | $90M | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | 8% | XXX | XXX | XXX |
| EBIT Margin | 5% | XXX | 5% | XXX | XXX | XXX |
| Net Profit | $57M | XXX | $59M | XXX | XXX | XXX |
| Net Margin | 5% | XXX | 5% | XXX | XXX | XXX |
| Net Debt | — | — | $96M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Chong Kun Dang Pharma Stock Performance
Chong Kun Dang Pharma has current market cap of $805M, and enterprise value of $819M.
Market Cap Evolution
Chong Kun Dang Pharma's stock price is $61.10.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $819M | $805M | -0.5% | XXX | XXX | XXX | $4.45 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialChong Kun Dang Pharma Valuation Multiples
Chong Kun Dang Pharma trades at 0.7x EV/Revenue multiple, and 9.7x EV/EBITDA.
EV / Revenue (LTM)
Chong Kun Dang Pharma Financial Valuation Multiples
As of April 18, 2026, Chong Kun Dang Pharma has market cap of $805M and EV of $819M.
Equity research analysts estimate Chong Kun Dang Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Chong Kun Dang Pharma has a P/E ratio of 14.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $805M | XXX | $805M | XXX | XXX | XXX |
| EV (current) | $819M | XXX | $819M | XXX | XXX | XXX |
| EV/Revenue | 0.7x | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBITDA | 9.7x | XXX | 9.1x | XXX | XXX | XXX |
| EV/EBIT | 14.9x | XXX | 15.0x | XXX | XXX | XXX |
| EV/Gross Profit | 2.3x | XXX | 2.3x | XXX | XXX | XXX |
| P/E | 14.0x | XXX | 13.7x | XXX | XXX | XXX |
| EV/FCF | (117.5x) | XXX | (17.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Chong Kun Dang Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Chong Kun Dang Pharma Margins & Growth Rates
Chong Kun Dang Pharma's revenue in the last 12 month grew by 8%.
Chong Kun Dang Pharma's rule of 40 is 15% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Chong Kun Dang Pharma's rule of X is 27% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Chong Kun Dang Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Growth | 4% | XXX | (4%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 15% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 27% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 9% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 26% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Chong Kun Dang Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Chong Kun Dang Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Design Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Vor Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| ARS Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Lexicon Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Bioage Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Chong Kun Dang Pharma M&A Activity
Chong Kun Dang Pharma acquired XXX companies to date.
Last acquisition by Chong Kun Dang Pharma was on XXXXXXXX, XXXXX. Chong Kun Dang Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Chong Kun Dang Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialChong Kun Dang Pharma Investment Activity
Chong Kun Dang Pharma invested in XXX companies to date.
Chong Kun Dang Pharma made its latest investment on XXXXXXXX, XXXXX. Chong Kun Dang Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Chong Kun Dang Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Chong Kun Dang Pharma
| When was Chong Kun Dang Pharma founded? | Chong Kun Dang Pharma was founded in 1941. |
| Where is Chong Kun Dang Pharma headquartered? | Chong Kun Dang Pharma is headquartered in South Korea. |
| Who is the CEO of Chong Kun Dang Pharma? | Chong Kun Dang Pharma's CEO is Young-joo Kim. |
| Is Chong Kun Dang Pharma publicly listed? | Yes, Chong Kun Dang Pharma is a public company listed on Korea Exchange. |
| What is the stock symbol of Chong Kun Dang Pharma? | Chong Kun Dang Pharma trades under 185750 ticker. |
| When did Chong Kun Dang Pharma go public? | Chong Kun Dang Pharma went public in 2013. |
| Who are competitors of Chong Kun Dang Pharma? | Chong Kun Dang Pharma main competitors are Design Therapeutics, Vor Biopharma, ARS Pharmaceuticals, Lexicon Pharmaceuticals. |
| What is the current market cap of Chong Kun Dang Pharma? | Chong Kun Dang Pharma's current market cap is $805M. |
| What is the current revenue of Chong Kun Dang Pharma? | Chong Kun Dang Pharma's last 12 months revenue is $1B. |
| What is the current revenue growth of Chong Kun Dang Pharma? | Chong Kun Dang Pharma revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Chong Kun Dang Pharma? | Current revenue multiple of Chong Kun Dang Pharma is 0.7x. |
| Is Chong Kun Dang Pharma profitable? | Yes, Chong Kun Dang Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Chong Kun Dang Pharma? | Chong Kun Dang Pharma's last 12 months EBITDA is $84M. |
| What is Chong Kun Dang Pharma's EBITDA margin? | Chong Kun Dang Pharma's last 12 months EBITDA margin is 7%. |
| What is the current EV/EBITDA multiple of Chong Kun Dang Pharma? | Current EBITDA multiple of Chong Kun Dang Pharma is 9.7x. |
| What is the current FCF of Chong Kun Dang Pharma? | Chong Kun Dang Pharma's last 12 months FCF is ($7M). |
| What is Chong Kun Dang Pharma's FCF margin? | Chong Kun Dang Pharma's last 12 months FCF margin is (1%). |
| What is the current EV/FCF multiple of Chong Kun Dang Pharma? | Current FCF multiple of Chong Kun Dang Pharma is (117.5x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.